Clinical trial Recruiting at 1 site Phase 3 Interventional Ages 18 to 65

Minimally invasive treatment with i-PRF and xenograft for Class II furcation defects in mandibular molars

Official title: Clinical and Radiographic Evaluation of Minimally Invasive Surgical Technique With Xenograft and Injectable Platelet Rich Fibrin Versus Injectable Platelet Rich Fibrin Alone in the Treatment of Class II Mandibular Furcation Defects: A Randomized Clinical Trial

Run by Cairo University · NCT07876973 · Data updated 2026-11-12

This study tests whether using injectable platelet-rich fibrin (i-PRF) with or without a xenograft can improve healing for Class II furcation defects in lower molars after periodontal therapy.

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years to 65 Years
SexAll
Enrollment24 (estimated)
SponsorCairo University
Academic / other
Locations1 site (Cairo, Cairo Governorate)
StatusRecruiting
StartedNovember 2026
Main results expectedMay 2027
Study endsMay 2028
Registry record updatedOctober 15, 2026
Trial IDNCT07876973 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18 years or older with stage III/IV periodontitis and a buccal or lingual Class II furcation defect in a non-mobile mandibular molar after initial therapy, with good oral hygiene and commitment to 12-month follow-up.

Probably not a fit

Patients with smoking >10 cigarettes per day, pregnant or lactating individuals, or those with buccal/lingual defects or other exclusion criteria may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 3 interventional trial compares two minimally invasive surgical approaches for managing Class II furcation defects in mandibular molars: i-PRF alone versus i-PRF combined with a xenograft. Participants are adults with stage III or IV periodontitis and a specific furcation defect who have completed non-surgical therapy. The study aims to measure clinical attachment and radiographic bone changes to determine which approach better promotes regeneration and reduces disease progression. Follow-up lasts 12 months to assess stability and outcomes. Lead sponsorship is Cairo University, conducted at the Cairo Faculty of Dentistry.

Why it matters

Potential benefit: If successful, patients could experience improved gum attachment and bone support around affected molars, potentially reducing tooth loss.

How similar studies have gone: Prior approaches using regenerative techniques show promise in furcation therapy, but this exact comparison between i-PRF alone and i-PRF with xenograft in Class II defects is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients with healthy systemic condition
* Adult patients (18 years old and older)
* Patients with stage lll or IV periodontitis.
* Patients having a buccal or lingual degree II A or B furcation defect in periapical-lesion free and not mobile first or second mandibular molars with horizontal attachment loss HCAL \>3 mm and probing depth PD ≥5 mm in the mid-buccal or mid-lingual sites when evaluated 12 weeks after non-surgical periodontal therapy.
* Patients with full mouth plaque score\<10% on the day of the surgery.
* Patients with full mouth bleeding score\<10% on the day of the surgery.
* Compliance with good oral hygiene.
* Patients accept 12-months follow-up period (cooperative patients).
* Patients provide an informed consent.

Exclusion Criteria:

* Ongoing drug therapy that might have an impact on the clinical signs and symptoms of periodontitis.
* Defects that involve the buccal and lingual sites.
* Smokers ˃ 10 cigarettes / day
* Pregnant and lactating female

Where it's running

  • Faculty of Dentistry,Cairo University
    Cairo, Cairo Governorate, Egypt
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.